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Abstract: Fibromyalgia (FM) is a complex syndrome characterized by chronic widespread 
musculoskeletal pain which is often accompanied by multiple other symptoms, including 
fatigue, sleep disturbances, decreased physical functioning, and dyscognition. Due to these 
multiple symptoms, as well as high rates of comorbidity with other related disorders, patients 
with FM often report a reduced quality of life. Although the pathophysiology of FM is not com-
pletely understood, patients with FM experience pain differently from the general population, 
most likely due to dysfunctional pain processing in the central nervous system leading to 
both hyperalgesia and allodynia. In many patients with FM, this aberrant pain processing, 
or central sensitization, appears to involve decreased pain inhibition within the spinal tract, 
which is mediated by descending pathways that utilize serotonin, norepinephrine, and other 
neurotransmitters. The reduced serotonin and norepinephrine levels observed in patients with FM 
suggest that medications which increase the levels of these neurotransmitters, such as serotonin 
and norepinephrine reuptake inhibitors (SNRIs), may have clinically beneficial effects in FM and 
other chronic pain conditions. Milnacipran is an SNRI that has been approved for the management 
of FM. In clinical trials, treatment with milnacipran for up to 1 year has been found to improve 
the pain and other symptoms of FM. Because FM is characterized by multiple symptoms that 
all contribute to the decreased quality of life and ability to function, the milnacipran pivotal 
trials implemented responder analyses. These utilized a single composite endpoint to identify 
the proportion of patients who reported simultaneous and clinically significant improvements in 
pain, global disease status, and physical function. Other domains assessed during the milnacipran 
trials include fatigue, multidimensional functioning, mood, sleep quality, and patient-reported 
dyscognition. This review article provides information intended to help clinicians make informed 
decisions about the use of milnacipran in the clinical management of patients with FM. It draws 
primarily on results from 2 of the pivotal clinical trials that formed the basis of approval of 
milnacipran in the United States by the Food and Drug Administration.
Keywords: fibromyalgia, milnacipran, pain, serotonin and norepinephrine reuptake inhibitors, 
SNRI
Introduction
Fibromyalgia (FM) is a chronic pain disorder that affects 0.5% to 5% of the general 
population worldwide, more frequently in women than in men.1–3 The management of 
this disorder is complicated by the occurrence not only of pain, but of multiple other 
symptoms including fatigue, stiffness, sleep disturbances, physical dysfunction, and 
cognitive problems.4–6 It is also complicated by frequent comorbidity with conditions that 
share clinical and genetic characteristics and possibly a common pathophysiology. These 
comorbid conditions include low back pain, diabetic peripheral neuropathy, chronic Neuropsychiatric Disease and Treatment 2010:6
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fatigue syndrome, irritable bowel syndrome (IBS), migraine 
headache, interstitial cystitis, multiple chemical sensitivities, 
and temporomandibular disorder (TMD).5,7 The common 
theme to these conditions appears to be heightened sensitivity 
to discomfort/stimuli in various regions of the body.
Patients with FM often experience a significantly 
diminished quality of life, and frequently report an inability 
to work and feelings of isolation due to their withdrawal from 
social activities.5,8 FM can result in distressing physical, social 
and psychological consequences. Therefore, the approval of 
3 agents over the past few years for the management of FM 
represents important progress in the ongoing development 
of evidence-based therapies for FM.
In the late 1990s, Cypress Bioscience, Inc. observed a 
large, unmet medical need revolving around the satisfactory 
treatment of chronic pain patients who were being diagnosed 
with FM. Although the FM diagnosis was somewhat 
controversial at the time, there was a large group of patients 
with numerous somatic complaints who were dissatisfied with 
their current health status. Moreover, physicians who man-
aged FM patients were expressing frustration with the lack of 
effective treatment options. Various medications were being 
used off-label to treat these patients, including tricyclic anti-
depressants (TCAs), selective serotonin reuptake inhibitors 
(SSRIs), opioids, nonsteroidal anti-inflammatory drugs 
(NSAIDs), growth hormone, corticosteroids, and sedative 
hypnotics. While the TCAs have been found to provide 
some relief from FM symptoms (particularly sleep-related 
complaints), their use is often limited by safety and tolerability 
considerations.9,10 The SSRIs offer a better tolerability profile, 
but results from clinical trials in patients with FM have been 
disappointing.11,12 Evidence for the other medications such as 
opioids and NSAIDs is either lacking or weak.11,13
In response to this unmet need in FM, Cypress began 
searching for a medication with a suitable neurotransmitter 
reuptake profile that could be developed as a potential first-line 
treatment option for patients with FM. One factor contributing 
to the choice of milnacipran for clinical development was 
the extensive safety data that already existed for this drug. 
Although milnacipran was not commercially available in the 
United States before its approval for the management of FM 
in 2009, it had been widely used in Europe (since 1997) and in 
Asia (since 2000) for the treatment of major depressive disor-
der. Its tolerability in depressed patients had been established 
in a number of clinical trials14 and was supported by several 
million patient-months of postmarketing safety data at the 
time Cypress licensed the rights for US development. Pierre 
Fabre Médicament, the original developer of milnacipran, 
was the licensor and still maintains the global milnacipran 
safety database.
The scientific rationale behind the development 
of milnacipran for FM was that, as a serotonin and 
norepinephrine reuptake inhibitor (SNRI), this drug should 
have clinically significant analgesic effects. In the central 
nervous system, both serotonin and norepinephrine have 
been found to play important roles in pain perception via 
their involvement in descending antinociceptive pathways.15 
Dysfunction in these descending pathways is thought to 
result in the hyperalgesic (heightened sensitivity to pain) 
and allodynic (painful response to nonpainful stimuli) states 
experienced by patients with FM and other related central 
sensitization syndromes such as IBS and TMD.16,17 The poten-
tial benefit of milnacipran in the treatment of FM was further 
supported by analgesic effects of SNRIs in animal models of 
pain,18 as well as findings showing decreased cerebrospinal 
fluid levels of serotonin and norepinephrine metabolites 
in patients with FM.19 Moreover, therapeutic benefits in 
FM had already been observed with drugs that inhibit the 
reuptake of both serotonin and norepinephrine, such as the 
TCA, amitriptyline.20,21 However, it should be noted that 
amitriptyline has not been tested in recent clinical trials using 
the same rigorous standards currently required by the US 
Food and Drug Administration (FDA) for approval of drugs 
for the management of FM. For example, recent FM clinical 
trials with now-approved medications such as milnacipran 
had much larger sample sizes and longer treatment durations22 
than the older studies involving amitriptyline.10 In addition, 
these more recent studies have consistently implemented mul-
tiple efficacy measures, including pain, global improvements, 
fatigue, mood, and multidimensional functioning in an effort 
to address the complex, multisymptomatic nature of FM.
Unlike the TCAs, milnacipran has no significant direct 
action on adrenergic, muscarinic, or histaminergic receptors – 
pharmacologic actions associated with many of the unpleas-
ant side effects of TCAs.23 Based on this pharmacologic 
profile, it was postulated that milnacipran would be clinically 
beneficial to patients with FM, providing improvements in 
pain with fewer adverse effects. Moreover, it was thought that 
a dual reuptake inhibitor would have more potential as an 
analgesic than medications that selectively block the reuptake 
of serotonin, which have not consistently demonstrated effec-
tiveness in treating FM symptoms.11,24 Interestingly, drugs that 
selectively target noradrenergic activity alone also appear to 
have limited efficacy in patients with FM.22 This suggests that 
both noradrenergic and serotoninergic activity are required 
to produce clinically significant pain relief.Neuropsychiatric Disease and Treatment 2010:6
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Milnacipran received its approval for the management of 
FM based on the safety and efficacy results of 2 pivotal trials 
conducted in the United States.25,26 In addition to reviewing 
the data from these trials, this article describes the various 
outcome measures that were used to establish the efficacy 
of milnacipran in patients with FM. The aim of this review 
article is to highlight the results of these clinical trials in 
order to provide clinicians with a better understanding of 
milnacipran as a treatment option in FM.
Pharmacology
Milnacipran is highly water soluble, leading to rapid and wide 
absorption, with maximum concentration observed within 
2 to 4 hours after dosing.27,28 The bioavailabilty of milnacipran 
is high (approximately 85% to 90%), and absorption is not 
affected by food intake. Milnacipran undergoes minimal 
first-pass metabolism, with approximately 55% of the 
drug excreted unchanged in urine.28 Its relatively short 
half-life (approximately 6 to 8 hours) is compatible with 
the recommended twice-daily dosing.28 Pharmacokinetic 
studies indicate that dose adjustment is not necessary 
based on age, gender, mild-to-moderate renal impair-
ment,29 or mild-to-moderate hepatic impairment.30 How-
ever, caution should be exercised in patients with moderate 
renal impairment or severe hepatic impairment. In patients 
with severe renal impairment, the maintenance dose of 
milnacipran should be reduced by approximately 50% to 
50 mg/day (25 mg twice daily).
The low extent of hepatic metabolism, low protein 
binding (13%), and minimal effects on cytochrome P450 
enzymes28,31,32 indicate a low potential for pharmacoki-
netic drug-drug interactions. In healthy volunteers, co-
administration of carbamazepine, digoxin, and lorazepam 
did not have clinically meaningful effects on the pharma-
cokinetics of milnacipran. Switching from fluoxetine to 
milnacipran also did not have an effect on milnacipran 
pharmacokinetics.28 In vitro, milnacipran did not demonstrate 
any significant affinity for adrenergic, serotonergic, dopami-
nergic, opiate, histaminergic, muscarinic, benzodiazepine, or 
gamma-aminobutyric acid receptors.28 These pharmacologic 
characteristics of milnacipran may be advantageous for the 
treatment of patients with FM, many of whom routinely take 
multiple medications or experience chemical sensitivities.
Clinical efficacy of milnacipran  
in FM trials
After the completion of a phase 2 trial that demonstrated the 
potential therapeutic benefits of milnacipran for patients with 
FM,33 Cypress Bioscience partnered with Forest Laboratories, 
Inc. to continue the clinical development of this drug for the 
management of FM. To date, 3 randomized, double-blind, 
placebo-controlled, multicenter phase 3 trials have been 
completed in the United States,25,26,34 and a phase 3 trial 
sponsored by Pierre Fabre Médicament has been conducted in 
Europe.35 This review focuses on data from the first 2 pivotal US 
trials upon which the FDA approval was based.25,26 Most of these 
data have been previously published or presented at scientific 
meetings; some of the information included in this review, 
however, is from data on file (Forest Laboratories, Inc.).
The first US pivotal trial included 888 patients with FM 
(based on the 1990 American College of Rheumatology [ACR] 
criteria for FM)36 and lasted 6 months (Study 1).25 The second 
included 1196 patients and lasted 3 months (Study 2).26 In both 
trials, patients were randomized to placebo, milnacipran 
100 mg/day, or milnacipran 200 mg/day. In Study 1, twice as 
many patients were randomized to the 200 mg/day group than 
were randomized to either the 100 mg/day or placebo groups 
in order to better assess the long-term effects of this higher 
dose. Patients enrolled in the milnacipran trials were required to 
discontinue centrally acting pharmacotherapies and nonphar-
macologic therapies commonly used to treat FM symptoms. 
Provision for limited use of rescue medication with hydro-
codone was allowed in these 2 trials (dosage: 60 mg/day 
for 5 days). Patients were instructed not to take hydrocodone 
during the 48-hour period prior to scheduled study visits and 
the 2-week period prior to endpoint data collection. For patients 
who used rescue medication during the critical time periods, 
a prespecified data handling provision caused these patients 
to be analyzed as non-responders to treatment, regardless of 
their actual pain scores. The percentage of patients taking 
hydrocodone was similar in all treatment arms.
Patient characteristics
Baseline patient characteristics were similar between the first 2 
milnacipran FM pivotal trials. In both trials, the patients were 
mostly women (90%), mostly white (90%), and had a mean 
age of approximately 50 years.25,26 Based on the body mass index 
(BMI) criteria issued by the World Health Organization,37 more 
than 75% of the patients were either overweight (BMI 25 to 30) 
or obese (BMI 30) at baseline.38 Before initiating treatment, 
the patients were similarly impaired in terms of baseline pain 
scores39 and overall disease activity, as measured by the Fibro-
myalgia Impact Questionnaire (FIQ).40 Mean baseline scores on 
the Short Form-36 Health Survey (SF-36) Physical Component 
Summary (PCS) indicated that enrolled FM patients had mark-
edly decreased physical functioning compared to US norms.41 Neuropsychiatric Disease and Treatment 2010:6
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Patients with current major depressive episodes were excluded 
from the trials, but approximately 35% of randomized patients 
in both studies reported a history of depression.25,26 Additionally, 
mean baseline Beck Depression Inventory (BDI) scores in both 
trials were 14, indicative of mild depressive symptoms.
Composite responder analyses
The milnacipran trials were designed to evaluate the effect of 
milnacipran on multiple symptom domains of FM, including 
pain, fatigue, global improvement, sleep, and physical and 
mental functioning. The outcomes evaluated in these studies 
are consistent with the key symptom domains proposed by 
the Outcome Measures in Clinical Rheumatology Trials 
(OMERACT) fibromyalgia working group.42–44 One type of 
efficacy endpoint recognized by OMERACT for its useful-
ness in FM clinical trials is the composite responder index.43,44 
This identifies the proportion of individual patients who 
have simultaneous, clinically meaningful improvements in 
multiple symptom domains. Composite endpoints have been 
used in clinical trials for various rheumatologic conditions, 
including rheumatoid arthritis45 and osteoarthritis,46 and 
provide information about specific patient responses as 
opposed to group mean changes. Although composite 
endpoints have some limitations,47 one strength is that 
they are inherently conservative estimates of clinical effi-
cacy. Patients who do not meet the criteria for each of the 
component domains cannot be counted as having responded 
to treatment, even if they show dramatic improvement for 
a single domain. In other words, composite endpoints can 
only be as robust as their weakest constituent component 
(ie, the one most difficult to change) and require that the 
therapy produces clinically significant changes in multiple 
domains in the same patient. As such, they set a high hurdle 
for success.
At the time the milnacipran studies were designed, it was 
not clear whether there was an appropriate instrument for 
the assessment of physical function as part of a composite 
responder definition. Therefore, 2 definitions of response 
were evaluated during the pivotal registration trials: 
a 2-measure composite responder analysis that required 
simultaneous improvements in pain and global status; 
and a more stringent 3-measure composite that required 
simultaneous improvements in pain, global status, and 
physical function.25,26 To be classified as 2-measure composite 
responders, individual patients were required to experience 
30% improvement from baseline in pain, as measured by 
Visual Analog Scale (VAS) 24-hour recall scores (recorded 
on a patient experience diary [PED], as described below), 
and a rating of “Much Improved” or “Very Much Improved” 
on the Patient Global Impression of Change (PGIC). Patients 
who experienced a 6-point improvement from baseline 
in their SF-36 PCS score, in addition to meeting the pain 
and PGIC criteria, were classified as 3-measure composite 
responders. All of the definitions of improvement were 
based on changes that met or exceeded established minimal 
clinically important differences for those measures.48–50
All statistical analyses were conducted on the intent-to-
treat (ITT) population. Several imputation methods were used 
to handle missing data in these registration trials. Baseline 
observation carried forward (BOCF), a conservative approach 
requested by the FDA for the approval of milnacipran for 
the management of FM,51 was the primary imputation 
method for analyzing the composite responder endpoints. 
In BOCF, a patient who does not successfully complete the 
final trial visit – irrespective of the reason – is declared a 
nonresponder, regardless of the actual data recorded up to 
that point. Sensitivity analyses were also conducted using 
last observation carried forward (LOCF) and observed cases 
(OC). LOCF is a widely employed imputation method that 
uses the last recorded value for patients with missing data, 
while OC is a straightforward method that only analyzes 
recorded observations and does not impute missing data. 
As an estimate of outcomes among patients who comply with 
and tolerate treatment,52 OC analyses of the milnacipran data 
may provide practicing physicians with useful information. 
OC results are therefore highlighted in this summary.
Patients who were treated with milnacipran experienced 
multidimensional improvements in pain, global status, and 
physical function. After 3 months of treatment in each of 
the pivotal studies, a significantly higher proportion of 
patients in the milnacipran groups met the 2-measure and 
3-measure composite responder criteria, as compared with 
the placebo group (P  0.01, both doses vs placebo; OC) 
(Figure 1).25,26 For the more stringent 3-measure composite 
analysis, response rates among milnacipran-treated patients 
were approximately twice the rates found in placebo-treated 
patients. Results after 6 months of treatment were similar to 
those found at the 3-month endpoint. At 6 months, response 
rates for the 2-measure composite responder analysis were 
43.8%, 45.2%, and 27.9% for milnacipran 100 mg/day, 
200 mg/day, and placebo, respectively (P  0.05, both doses 
vs placebo; OC).25
Pain
Improvement in pain was included as part of the composite 
responder analyses because chronic widespread pain is Neuropsychiatric Disease and Treatment 2010:6
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central to the definition of FM and is rated by both patients 
and physicians as the most important core domain to be 
assessed in FM clinical trials.42,43 In addition to being 
included as one component of the primary composite end-
points, pain was evaluated separately in the milnacipran 
trials using various secondary outcome measures, given 
the primacy of this symptom in the experience of patients 
with FM. Pain data was collected on electronic PEDs that 
prompted patients to record their 24-hour recall pain, weekly 
recall pain, and current level of pain (“real-time”) by mark-
ing VAS scales displayed on these hand-held electronic 
diaries. The PEDs, which were customized for use in the 
milnacipran trials, provided patients with a more accurate 
tool to report on their pain experiences. In post hoc analyses 
of the milnacipran pivotal trials,53,54 these electronic PEDs 
were found to be more discriminatory and sensitive than 
paper-based pain assessments. This was probably due to the 
minimization of recall bias and the ability to capture data 
in the patients’ home environment. Use of these electronic 
diaries also helped to satisfy the FDA’s recent rigorous 
approach to the use of patient-reported outcomes in registra-
tion trials. At the time of application for FDA approval, over 
1 million pain data points had been collected from patients 
enrolled in the milnacipran FM trials. The PED pain data 
were supplemented by paper VAS pain assessments captured 
from patients at each study visit.
Milnacipran has proven to be effective in reducing 
FM pain.25,26,33–35 Compared with placebo, milnacipran 
was associated with significant improvements in PED and 
paper-based VAS pain measures.25,26 Significant sustained 
pain reductions were observed as early as 1 week after 
stable-dose treatment with milnacipran (P  0.05 vs 
placebo), and maximal pain relief was reached by 9 weeks 
of treatment (Figure 2).25,26 The pain component of the 
composite responder analysis (ie, 30% improvement from 
baseline PED VAS 24-hour recall pain score) represents 
a clinically meaningful improvement in FM pain.48,49 
A significantly higher proportion of patients experienced 
30% improvements in pain with milnacipran than with 
placebo in Study 1 (52.8%, 100 mg/day; 56.2%, 200 mg/day; 
placebo, 40.2%; P  0.05, both doses vs placebo; OC)25 and 
Study 2 (52.3%, 100 mg/day; 54.8%, 200 mg/day; 38.4%, 
placebo; P  0.01, both doses vs placebo; OC).26
A post hoc analysis of these 2 pivotal trials was conducted 
to determine the proportion of days in which patients 
experienced a 30% improvement in pain.55 Over a 3-month 
treatment period, patients treated with milnacipran vs placebo 
had a significantly higher percentage of days with clinically 
meaningful pain relief (45%, 100 mg/day; 46%, 200 mg/day; 
33%, placebo; P  0.0001, both doses vs placebo; OC). 
Significant differences between milnacipran and placebo in 
the proportion of pain relief days were also detected using a 
more stringent measure of 50% improvement from baseline 
in PED VAS 24-hour recall pain scores (27%, 100 mg/day; 
29%, 200 mg/day; 18%, placebo; P  0.0001, both doses 
vs placebo; OC).
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Patient global
“Patient global” is one of the core domains identified by 
OMERACT as being essential for inclusion in FM clinical 
trial designs.42–44 While most FM patients have symptoms 
involving multiple domains, not all patients rate all symp-
toms as being of similar importance. Therefore, a measure 
that implicitly evaluates those domains of most importance 
to an individual patient has practical utility and face validity. 
In the milnacipran studies, patient global was incorporated into 
the composite responder endpoints using the PGIC, a simple 
instrument that asks patients to rate their overall improvement 
by completing a single statement (“Since the start of the study, 
overall, my fibromyalgia is”) using a Likert scale ranging from 
1 (“Very Much Improved”) to 7 (“Very Much Worse”). After 
3 months of treatment, approximately one-half of the patients 
treated with milnacipran had marked global improvements 
(ie, PGIC score 2) compared with approximately one-third 
of the placebo-treated patients (49.4%, 100 mg/day; 52.8%, 
200 mg/day; 33.8%, placebo; OC; pooled data on file).
In analyses conducted to evaluate which symptom 
domains in the milnacipran trials were associated with 
global well-being, pain was the strongest independent factor 
correlating with PGIC scores among patients who reported 
any global improvements (PGIC score 3).56 Vitality, sleep, 
dyscognition, and physical function were also significantly 
and independently associated with PGIC improvements. 
These findings are similar to those recently reported by 
OMERACT.44 Using the PGIC as a surrogate of overall 
improvement, OMERACT researchers examined data from 
10 clinical trials of FM and found that measures of pain, 
fatigue, multidimensional function, physical function, and 
stiffness had the highest correlation with PGIC ratings. 
These types of correlations suggest that overall changes in 
patient global well-being reflect changes in multiple FM 
symptoms, underscoring the need for therapies that have 
multidimensional clinical benefits.
Functioning
Given the impact of pain on daily functioning, patient-
reported quality of life measures have been increasingly 
utilized in pain clinical trials57 and are now considered to be 
an essential area of assessment for the approval of chronic 
pain medications.4 OMERACT has similarly recognized 
the importance of using quality of life measures to assess 
the efficacy of FM therapies.43,44 One such measure is the 
SF-36, a validated health status scale that has been used in 
over 70 studies involving FM clinical patients.44,58 The SF-36 
includes 36 items assessing 8 domains (physical functioning, 
bodily pain, role limitations due to physical problems, role 
limitations due to emotional problems, general health, mental 
health, energy/vitality, and social functioning) from which 
the PCS and Mental Component Summary (MCS) scores 
are derived.41
In a recent review comparing the health status profile of 
individuals with FM with that of the general population and 
patients with other health conditions, FM patients were found 
to have poorer scores on all 8 SF-36 domains than did patients 
with hypertension, recent acute myocardial infarction, type II 
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diabetes, congestive heart failure, or chronic obstructive 
pulmonary disease.58 This analysis also found that high 
levels of bodily pain and decreased energy/vitality scores 
were characteristic of FM, as compared with other chronic 
pain conditions (ie, herniated disc, epicondylitis, osteoar-
thritis, and rheumatoid arthritis). Such findings underscore 
the importance of prescribing FM medications that not only 
reduce pain, but also improve multidimensional functioning 
and increase energy/vitality.
In the pivotal trials, milnacipran treatment improved 
physical and mental functioning in patients with FM, as 
demonstrated by significant differences between active drug 
and placebo in the SF-36 PCS, SF-36 MCS, and each of the 
individual SF-36 domains (Table 1, pooled data on file). 
Clinically meaningful improvement for the SF-36 PCS was 
defined in the milnacipran trials as 6-point improvement 
from baseline score, a more conservative criterion than 
the minimum clinically important differences (SF-36 PCS 
changes, 2.5 to 5.0 points) that have been established for 
various rheumatic conditions.50 After 3 months of treatment, 
a higher proportion of milnacipran-treated patients were 
found to have clinically meaningful improvements in the 
SF-36 PCS as compared with placebo-treated patients 
(44.5%, 100 mg/day; 42.5%, 200 mg/day; 32.7%, placebo; 
OC; pooled data on file).
Fatigue
Fatigue is a common complaint among patients with 
FM, usually described as being physically or emotionally 
draining.4,6 Like pain, fatigue is a constant presence that 
fluctuates in intensity throughout the day, affecting a patient’s 
ability to perform daily tasks, to function in the work force, 
and to enjoy social or recreational activities.4,6,59 Therefore, 
medications that reduce fatigue are important to both patients 
with FM and treating physicians.
To assess the efficacy of milnacipran on fatigue, the 
pivotal trials utilized the Multidimensional Fatigue Inventory 
(MFI), a 20-item self-report instrument that measures several 
dimensions of fatigue: general fatigue, physical fatigue, 
mental fatigue, reduced motivation, and reduced activity.60 
The MFI has been used to assess fatigue levels in various 
chronic conditions such as rheumatoid arthritis,61 ankylosing 
spondylitis,62 and Sjögren’s syndrome.63 In the milnacipran 
pivotal trials, significant improvements in fatigue were 
observed with milnacipran 200 mg/day compared with 
placebo, as evidenced by MFI total and all subscale scores 
(Table 1).64 Patients treated with milnacipran 100 mg/day 
compared with placebo showed significant improvements 
in MFI total scores and subscale scores of general fatigue, 
physical fatigue, and reduced motivation.
Cognitive impairment
The cognitive functions most affected in patients with FM are 
working memory, episodic memory, and semantic memory; 
other impairments include attentional control, susceptibility 
to distraction, and loss of vocabulary.65 Patients who have 
cognitive dysfunction often describe their experiences 
as feeling disorganized, having difficulty planning, and 
being unable to remember words.59 Like pain and fatigue, 
this “fibro-fog” affects daily functioning, particularly with 
regard to a patient’s ability to work and drive.59
The milnacipran clinical trials assessed self-reported 
cognitive function in FM patients by using the Multiple 
Ability Self-Report Questionnaire (MASQ). The MASQ 
assesses 5 cognitive domains: language, verbal memory, 
visuo-perceptual ability, visual memory, and attention.66 
Significant improvements in the MASQ total score were 
Table 1 Additional significant outcomes in fibromyalgia patients 
receiving 3 months of milnacipran treatment
Symptom  
domain
Outcome  
measures
Treatment 
groupsa
Function SF-36 PCS 100, 200
SF-36 MCS 200
SF-36 bodily pain 100, 200
SF-36 physical functioning 100, 200
SF-36 energy/vitality 100, 200
SF-36 role limitations-physical 200
SF-36 role limitations-emotional 200
SF-36 general health 200
SF-36 mental health 200
SF-36 social functioning 200
Fatigue MFi total 100, 200
MFi general fatigue 100, 200
MFi physical fatigue 100, 200
MFi mental fatigue 200
MFi reduced motivation 100, 200
MFi reduced activity 200
Cognition MASQ total 200
MASQ attention 100, 200
MASQ verbal memory 100, 200
aTreatment groups in pooled analysis of 2 pivotal trials25,26 demonstrating significant 
least square mean differences from placebo in change from baseline score 
(P  0.05, OC).
Abbreviations: 100, milnacipran 100 mg/day; 200, milnacipran 200 mg/day; MASQ, 
Multiple Ability Self-Report Questionnaire; MCS, Mental Component Summary; MFI, 
  Multidimensional Fatigue inventory; OC, observed cases; PCS, Physical Component 
Summary; SF-36, Short Form-36 Health Survey.Neuropsychiatric Disease and Treatment 2010:6
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observed in patients treated with milnacipran 200 mg/day 
compared with placebo (Table 1, pooled data on file). 
Similarly, significant results with both doses of milnacipran 
were found for the MASQ verbal memory and attention 
domains, both of which are reflective of FM cognitive 
deficits. These results indicate that milnacipran improves 
cognitive function in patients with FM, particularly in the 
domains (eg, memory and attention)65 most affected by this 
disorder.
Long-term studies
Until recently, FM clinical trials have tended to be short 
in duration, generally lasting 3 months or less. Given the 
chronic nature of FM, experts in the field have recommended 
that longer clinical trials be conducted in order to evaluate 
whether the benefits of FM treatments persist over time.21,67 
To this end, 2 randomized, double-blind extension studies 
of milnacipran have been conducted in the United States: 
a 28-week extension study to the 6-month pivotal trial 
(N = 449)68 and an extension study adding up to 39 weeks 
to the 3-month pivotal trial (N = 384).69 Additionally, a 
12-month extension of the 3-month European milnacipran 
trial has been completed.70 In the US studies, patients who 
received milnacipran 200 mg/day during the lead-in pivotal 
trials, were continued on the same dosage in a blinded 
fashion during the extension studies. Patients who received 
placebo or milnacipran 100 mg/day were re-randomized to 
milnacipran 100 mg/day or 200 mg/day.
Results from the extension studies indicate that milnacipran 
effectively improves the pain and other symptoms of FM for 
at least 1 year.68,69 The clinical benefits of milnacipran were 
maintained in patients who received milnacipran in both the 
lead-in and extension studies (ie, 12 months of continuous mil-
nacipran treatment). In these patients, efficacy outcomes at the 
end of the extension study (eg, pain VAS scores, FIQ total and 
physical function scores, PGIC scores) were similar to those 
observed at the end of the lead-in study. A subgroup of patients 
(n = 100) re-randomized from placebo to milnacipran 200 mg/
day after 6 months of placebo in the double-blind lead-in 
trial experienced additional improvements in pain, FIQ, and 
PGIC scores during the extension study period.68 By the 
end of 12 months, this subgroup of patients had achieved 
the same relative degree of pain and global improvement 
reported by those treated continuously with milnacipran 
for the entire 12 months. Results from another subgroup 
of patients who were re-randomized from 100 mg/day to 
200 mg/day (n = 92) indicate that some patients may benefit 
from increasing the milnacipran dosage.68 In these patients, 
additional improvements in pain and other outcomes were 
observed during the extension study period during which 
they received the higher dosage. Data from patients receiving 
milnacipran for up to 3 years in the US trials will be available 
after the conclusion of a currently ongoing study.
Safety and tolerability
The safety and tolerability information presented here is from 
patients with FM who were enrolled in the phase 2 clinical 
trial33 and the 2 pivotal registration trials.25,26 Together, these 
trials included 2209 patients, 1557 of whom were treated with 
milnacipran and 652 of whom received placebo.
Discontinuation due to adverse events (AEs) occurred in 
23.0% and 26.0% of patients receiving milnacipran 100 mg/day 
and 200 mg/day, respectively, compared with 12.1% of placebo-
treated patients.71 Nausea and palpitations were the only AEs 
resulting in discontinuation in 2% of milnacipran patients 
and at an incidence greater than placebo. Treatment-emergent 
AEs (TEAEs) in the milnacipran trials were generally mild 
to moderate in severity, with nausea being the most common 
TEAE in all treatment groups. The placebo-corrected rates of 
nausea for milnacipran 100 mg/day and 200 mg/day were 14.9% 
and 19.7%, respectively.71 Nausea typically occurred early in 
treatment and was generally manageable by recommending 
that medication be taken with food, incorporating gradual 
dose escalation, and providing patient counseling. While the 
clinical trials were designed to have relatively inflexible dose 
escalation phases lasting 2 weeks, recent anecdotal reports from 
commercial usage suggest that a slower, more flexible approach 
to dose increases may be beneficial.
Headache was the second most common TEAE, occurring 
in 18.6%, 17.2%, and 13.7% of all patients receiving mil-
nacipran 100 mg/day, 200 mg/day, and placebo, respectively.71 
TEAEs that occurred in 5% of all milnacipran-treated 
patients at an incidence at least twice that of placebo were 
constipation, hot flush, hyperhidrosis (sweating), palpitations, 
vomiting, increased heart rate, dry mouth, and hypertension. 
Most of the aforementioned TEAEs would appear to be directly 
related to the effect of increased norepinephrine levels in the 
periphery. No new safety concerns were observed with pro-
longed exposure to milnacipran in the extension studies.68,69
As with other drugs in this class, cardiovascular effects 
have been reported with milnacipran. In the FM clinical trials, 
treatment with milnacipran 100 mg/day was associated with 
mean increases in blood pressure up to 3.1 mmHg, as well 
as mean increases in pulse rate of 7 to 8 bpm.28 Potentially 
clinically significant increases in supine systolic blood 
pressure (180 mmHg with an increase of 20 mmHg) Neuropsychiatric Disease and Treatment 2010:6
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occurred rarely (0.2%) in patients from all treatment 
groups.71 Potentially clinically significant increases in supine 
diastolic blood pressure (110 mmHg with an increase 
of 15 mmHg) occurred in 0.9% of patients receiving 
milnacipran, compared with 0.3% of patients receiving 
placebo. Potentially clinically significant increases in 
supine pulse rate (120 bpm with an increase of 20 bpm) 
occurred in 0.7% and 0% of patients receiving milnacipran 
and placebo, respectively (pooled data on file). Results from 
a recently published study indicate that at supratherapeutic 
doses, milnacipran does not significantly affect cardiac 
repolarization or contribute to QTc prolongation.72
Milnacipran was not associated with weight gain, which 
can occur with other medications used to treat FM.73 During 
the course of therapy, patients who received milnacipran 
tended to lose weight. At 3 and 6 months, the proportion 
of patients with clinically significant weight loss (5% 
of baseline body weight) was significantly higher with 
milnacipran vs placebo (P  0.01, both doses vs placebo; 
both endpoints).38 Similar nausea rates in milnacipran-
treated patients who lost or gained weight indicate that this 
weight loss was unrelated to nausea. The lack of weight 
gain has been observed for up to 12 months of milnacipran 
treatment.68 In contrast to the use of SSRIs for FM,74 sexual 
side effects were reported in 1.0% of milnacipran-treated 
patients enrolled in the placebo-controlled FM trials (data 
on file). These findings of lack of sexual side effects were 
also supported by the lack of a significant difference between 
milnacipran and placebo groups on the Arizona Sexual 
Experience Scale.25 In the small population of males with 
FM (n = 87) included in the placebo-controlled trials, geni-
tourinary AEs were reported in at least 2% of male patients 
treated with milnacipran and occurred at a rate greater 
than in placebo-treated male patients.28 This observation is 
consistent with the mechanism of milnacipran in which the 
increased peripheral norepinephrine level causes an increase 
in muscle tone, including in the urethra.
Conclusion: place in therapy
The complexity and heterogeneity of FM limits the utility 
of single-instrument outcomes in determining therapeutic 
efficacy. The multifaceted approach used to evaluate effi-
cacy in the milnacipran clinical trials reflects ongoing 
discussions by groups such as OMERACT regarding the 
key domains and assessment tools needed to adequately 
evaluate FM outcomes.42–44 In the milnacipran clinical tri-
als, the implementation of 2 composite responder indices 
allowed investigators to identify the proportion of indi-
vidual patients who experienced simultaneous improve-
ments in multiple symptom domains. As the development of 
pharmacotherapies for FM and other chronic pain syndromes 
progresses, it is expected that other clinical studies, such as 
the recently reported trials with sodium oxybate,75,76 will 
continue to use such outcome measures in order to better 
address the multisymptomatic nature of these disorders.
Results of the responder analyses in the milnacipran trials 
indicate that the therapeutic benefits of this medication extend 
beyond its analgesic effects.25,26,34,35 Based on the OC analyses 
of patients who were compliant with treatment in the clinical 
trial program, the rate of response with milnacipran treat-
ment was approximately 50% on the 2-measure composite 
endpoint (clinically meaningful reduction in pain plus “much 
improved” or “very much improved” global status). These 
encouraging results suggest that if patients with FM are 
counseled on the importance of medication compliance and 
are adequately informed about the side effects of milnacipran, 
which are generally mild and transient, approximately half 
of these patients will achieve clinically significant and 
meaningful improvement in multiple domains.
There were no statistical differences in composite 
responder rates between milnacipran 100 mg/day and 
200 mg/day, although these trials were not powered to detect 
such differences. Moreover, with the exception of nausea, 
the AE profile was similar between the dosages. In clinical 
settings, however, some patients may benefit from the higher 
dose, as evidenced by results from the extension studies in 
which patients who were re-randomized to the higher dose 
for an additional 6 to 9 months of treatment experienced 
additional improvements in pain and multidimensional 
function. Thus, although milnacipran 100 mg/day is the 
recommended starting dose, some FM patients can be 
escalated to the higher dose on an as-needed basis and if 
tolerability allows. Due to the potential for cardiovascular 
side effects, blood pressure and pulse rate should be measured 
before starting therapy with milnacipran and periodically 
monitored in all patients throughout the course of treatment. 
If baseline hypertension or tachycardia is detected, this should 
be treated and controlled prior to starting therapy with any 
drug that impacts noradrenergic activity.
One aim of the milnacipran clinical development program 
was to differentiate the analgesic effects of milnacipran from 
possible antidepressant effects. Although milnacipran was 
found to relieve pain in both depressed and nondepressed 
FM patients during the phase 2 trial,33 a change was made 
in the phase 3 trial design to exclude patients with cur-
rent major depressive episodes, so that the analgesic and Neuropsychiatric Disease and Treatment 2010:6
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other therapeutic effects could be more clearly assessed 
in the absence of a potentially confounding effect on 
depression. In the phase 3 trials, improvements in pain and 
other efficacy outcomes were robust in nondepressed FM 
populations,25,26,34,35 with an analysis of Study 1 showing that 
milnacipran resulted in global improvements regardless of 
baseline depressive symptom severity.77
Standardized guidelines for the management of FM have 
not been established, although it has been recommended 
that drugs with strong clinical evidence be used as first-
line therapies in patients with moderate to severe pain.67 
Strong evidence has been found for all of the FDA-approved 
medications for FM (milnacipran, duloxetine, pregabalin),12 
although no direct comparisons between these medications 
can be made in the absence of head-to-head clinical trials. 
Making comparisons based on available clinical trial 
results is also not possible due to the use of different study 
designs and primary and secondary outcome measures in 
the trials.78 However, it has been suggested that SNRIs, 
such as milnacipran and duloxetine, may be tried in patients 
with comorbid mood disturbances and/or physical function 
deficits whereas pregabalin, an alpha-2-delta ligand, may 
be more appropriate for patients with prominent sleep 
disturbances or anxiety.24,67 For patients who have a partial 
response to monotherapies, combination treatment with 
medications having different mechanisms of action may 
be beneficial.67,79 The pending results from a multicenter, 
randomized, controlled pilot study investigating the addition 
of milnacipran to pregabalin treatment are expected to help 
clarify the potential benefits of combination therapy.80 Such 
research may soon be complemented by findings from genetic 
and pharmacogenetic studies,81 which are being conducted 
with the goal of allowing more personalized approaches to 
FM treatment in the future.
Although the approval of milnacipran and other 
medications represents progress in the treatment of FM, none 
of these treatments has proven to be completely effective 
in treating chronic pain conditions. Additional therapeutic 
approaches including combination and multimodal 
therapies will likely be needed. Development of personal-
ized approaches, perhaps coupled with agents that modulate 
other aspects of the CNS pain processing system, will be 
needed as we strive to improve the treatment of chronic pain 
conditions.
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